- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03877146
Calming Alternatives Learned During MRI-Guided Breast Biopsy (CALM)
September 23, 2020 updated by: Duke University
Calming Alternatives Learned During MRI-Guided Breast Biopsy (CALM)
The proposed randomized study evaluates whether a controlled breathing intervention could be efficacious for reducing pain in the MRI-guided breast biopsy setting.
Support for this intervention stems from experimental and clinical studies on the effects of controlled breathing on pain.
Implementing a controlled breathing intervention during MRI-guided breast biopsy has the potential to provide effective pain management in this outpatient setting.
The primary study objectives are to assess the feasibility, acceptability, and efficacy of a novel audio-recorded controlled breathing intervention for reducing breast and body pain in women undergoing MRI-guided breast biopsy.
The secondary study objectives are to evaluate the effects of controlled breathing on measures of physiological reactivity (i.e., blood pressure and heart rate), pain catastrophizing, and self-efficacy for pain and anxiety.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Cancer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women undergoing MRI-guided core needle breast biopsy at the Duke Cancer Institute
- Ability to speak and read in English
- Age ≥ 18 years
- Ability to provide meaningful consent
Exclusion Criteria:
- Hearing impairment that is documented in the medical record that would limit the use of the guided intervention or music
- Cognitive impairment that is documented in the medical record or results in being unable to provide meaningful consent
- Undergoing IV-administered sedation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Usual Care Control Condition
As part of usual care, participants will be provided with headphones to listen to music during the biopsy procedure.
Music options will include instrumental jazz, classical piano, harp and flute, and world music.
|
|
EXPERIMENTAL: Controlled Breathing Intervention
Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file.
Over the course of the 25-60-minute procedure, approximately 50% of the intervention will be spent completing controlled breathing.
The other 50% of the intervention will be spent listening to music, which is part of usual care.
Music options will include instrumental jazz, classical piano, harp and flute, nature sounds, and world music.
|
Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file.
The intervention will guide participants to breathe at a rate of six breaths per minute (approximately 50% of their normal breathing rate).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body pain pre-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale
Time Frame: Baseline
|
Body pain pre-biopsy will be will be assessed using four questions from the Brief Pain Inventory (BPI) Pain Severity Scale.
Women will be asked to rate 1) worst, 2) least, and 3) average body pain during the past week, as well as 4) current body pain on a scale from 0 (no pain) to 10 (pain as bad as it could be).
Consistent with BPI scoring, items will be averaged to create a composite score that had a possible range of 0 to 10 with higher scores indicating greater pain.
|
Baseline
|
Breast pain pre-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale
Time Frame: Baseline
|
Breast pain pre-biopsy will be will be assessed using four questions from the Brief Pain Inventory (BPI) Pain Severity Scale.
Women will be asked to rate 1) worst, 2) least, and 3) average breast pain during the past week, as well as 4) current breast pain on a scale from 0 (no pain) to 10 (pain as bad as it could be).
Consistent with BPI scoring, items will be averaged to create a composite score that had a possible range of 0 to 10 with higher scores indicating greater pain.
|
Baseline
|
Body pain after positioning on the MRI table: Numerical rating scale (NRS)
Time Frame: After positioning on the MRI table, within 1 minute
|
Body pain after positioning on the MRI table for the biopsy procedure will be will be assessed using a verbally-administered numerical rating scale (NRS) that ranges from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater pain.
|
After positioning on the MRI table, within 1 minute
|
Breast pain after local anesthetic injection: Numerical rating scale (NRS)
Time Frame: After each superficial local anesthetic injection, within 1 minute
|
Breast pain after each superficial local anesthetic injection during the biopsy procedure will be will be assessed using a verbally-administered numerical rating scale (NRS) that ranges from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater pain.
|
After each superficial local anesthetic injection, within 1 minute
|
Breast pain after deeper local anesthetic injection: Numerical rating scale (NRS)
Time Frame: After each deeper local anesthetic injection, within 1 minute
|
Breast pain after each deeper local anesthetic injection during the biopsy procedure will be will be assessed using a verbally-administered numerical rating scale (NRS) that ranges from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater pain.
|
After each deeper local anesthetic injection, within 1 minute
|
Body pain after introducer insertion: Numerical rating scale (NRS)
Time Frame: After last introducer insertion, within 1 minute
|
Body pain after the last introducer is inserted will be will be assessed using a verbally-administered numerical rating scale (NRS) that ranges from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater pain.
|
After last introducer insertion, within 1 minute
|
Breast pain after tissue sampling: Numerical rating scale (NRS)
Time Frame: After last tissue sampling at each biopsy site, within 1 minute
|
Breast pain after the last tissue sampling at each biopsy site will be will be assessed using a verbally-administered numerical rating scale (NRS) that ranges from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater pain.
|
After last tissue sampling at each biopsy site, within 1 minute
|
Body pain after introducer sheath removal: Numerical rating scale (NRS)
Time Frame: After last introducer sheath removal, within 1 minute
|
Body pain after the last introducer sheath is removed will be will be assessed using a verbally-administered numerical rating scale (NRS) that ranges from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater pain.
|
After last introducer sheath removal, within 1 minute
|
Body pain post-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale
Time Frame: Post-biopsy, within 1 minute
|
Body pain post-biopsy will be will be assessed using four questions from the Brief Pain Inventory (BPI) Pain Severity Scale.
Women will be asked to rate 1) worst, 2) least, and 3) average body pain during the biopsy procedure, as well as 4) current body pain on a scale from 0 (no pain) to 10 (pain as bad as it could be).
Consistent with BPI scoring, items will be averaged to create a composite score that had a possible range of 0 to 10 with higher scores indicating greater pain.
|
Post-biopsy, within 1 minute
|
Breast pain post-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale
Time Frame: Post-biopsy, within 1 minute
|
Breast pain post-biopsy will be will be assessed using four questions from the Brief Pain Inventory (BPI) Pain Severity Scale.
Women will be asked to rate 1) worst, 2) least, and 3) average breast pain during the biopsy procedure, as well as 4) current breast pain on a scale from 0 (no pain) to 10 (pain as bad as it could be).
Consistent with BPI scoring, items will be averaged to create a composite score that had a possible range of 0 to 10 with higher scores indicating greater pain.
|
Post-biopsy, within 1 minute
|
Body pain 24 hours post-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale
Time Frame: 24 hours post-biopsy
|
Body pain 24 hours post-biopsy will be will be assessed using four questions from the Brief Pain Inventory (BPI) Pain Severity Scale.
Women will be asked to rate 1) worst, 2) least, and 3) average body pain in the 24 hours post-biopsy, as well as 4) current body pain on a scale from 0 (no pain) to 10 (pain as bad as it could be).
Consistent with BPI scoring, items will be averaged to create a composite score that had a possible range of 0 to 10 with higher scores indicating greater pain.
|
24 hours post-biopsy
|
Breast pain 24 hours post-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale
Time Frame: 24 hours post-biopsy
|
Breast pain 24 hours post-biopsy will be will be assessed using four questions from the Brief Pain Inventory (BPI) Pain Severity Scale.
Women will be asked to rate 1) worst, 2) least, and 3) average breast pain in the 24 hours post-biopsy, as well as 4) current breast pain on a scale from 0 (no pain) to 10 (pain as bad as it could be).
Consistent with BPI scoring, items will be averaged to create a composite score that had a possible range of 0 to 10 with higher scores indicating greater pain.
|
24 hours post-biopsy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of pre-biopsy body pain sites: Body map
Time Frame: Baseline
|
To indicate the number of pre-biopsy body pain sites, participants will complete a full body map, indicating the locations of body pain.
|
Baseline
|
Number of pre-biopsy breast pain sites: Breast map
Time Frame: Baseline
|
To indicate the number of pre-biopsy breast pain sites, participants will complete a breast map (showing the chest, shoulders, and upper arms), indicating the locations of breast pain.
|
Baseline
|
Anticipated body pain: Anticipatory body pain scale
Time Frame: Baseline
|
Prior to biopsy, one question will be asked to assess anticipated body pain (i.e., "How much body pain do you think you will experience during the biopsy today?") on a scale from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater anticipated pain.
|
Baseline
|
Anticipated breast pain: Anticipatory breast pain scale
Time Frame: Baseline
|
Prior to biopsy, one question will be asked to assess anticipated breast pain (i.e., "How much breast pain do you think you will experience during the biopsy today?") on a scale from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater anticipated pain.
|
Baseline
|
Anxiety pre-biopsy: State Anxiety Scale of the State-Trait Anxiety Inventory (STAI)
Time Frame: Baseline
|
The State Anxiety Scale of the State-Trait Anxiety Inventory (STAI) will assess the degree of anxiety pre-biopsy.
Participants will rate each of the 20 items on a 5-point Likert scale, ranging from 1 (not at all) through 4 (very much).
Items will be summed, creating a total score (possible range: 20-80).
|
Baseline
|
Likelihood of cancer pre-biopsy: Likelihood of cancer scale
Time Frame: Baseline
|
Likelihood of cancer will be assessed pre-biopsy using a 1 single-item scale.
Participants will be asked to indicate what they were told regarding the likelihood of cancer from their recommending radiologist on a scale from 0 (not applicable - they did not discuss this with me) to 5 (high likelihood of cancer) with higher scores indicating a greater likelihood of cancer.
|
Baseline
|
Pain coping strategies pre-biopsy: Coping Strategies Questionnaire (CSQ)
Time Frame: Baseline
|
To assess the use of pain coping strategies pre-biopsy, participants will complete the 14-item Coping Strategies Questionnaire (CSQ).
Participants will rate how frequently they use seven pain coping strategies (two items per scale) on a scale ranging from 0 (not at all) to 6 (a lot).
Items will be averaged, giving a total score on each scale ranging from 0 to 6 with higher scores indicating greater use of pain coping strategies.
|
Baseline
|
Self-efficacy for pain and anxiety pre-biopsy: Self-efficacy for pain and anxiety scale
Time Frame: Baseline
|
To assess self-efficacy for managing pain and anxiety pre-biopsy, participants will complete a 4-item scale.
Items will be rated on a 10-point scale from 1 (not certain) to 10 (very certain).
Items will be averaged to create a composite score, ranging from 0 to 10 with higher scores indicating greater self-efficacy.
|
Baseline
|
Blood pressure pre-biopsy
Time Frame: Baseline
|
Blood pressure (systolic/diastolic) pre-biopsy will be measured using an MRI-compatible blood pressure cuff.
|
Baseline
|
Pulse pre-biopsy
Time Frame: Baseline
|
Heart rate pre-biopsy will be measured using an MRI-compatible pulse oximeter.
|
Baseline
|
Blood pressure after positioning on the MRI table
Time Frame: After positioning on the MRI table, within 1 minute
|
Blood pressure (systolic/diastolic) after positioning on the MRI table will be measured using an MRI-compatible blood pressure cuff.
|
After positioning on the MRI table, within 1 minute
|
Pulse after positioning on the MRI table
Time Frame: After positioning on the MRI table, within 1 minute
|
Heart rate after positioning on the MRI table will be measured using an MRI-compatible pulse oximeter.
|
After positioning on the MRI table, within 1 minute
|
Blood pressure after introducer insertion
Time Frame: After last introducer insertion, within 1 minute
|
Blood pressure (systolic/diastolic) after the last introducer is inserted will be measured using an MRI-compatible blood pressure cuff.
|
After last introducer insertion, within 1 minute
|
Pulse after after introducer insertion
Time Frame: After last introducer insertion, within 1 minute
|
Heart rate after the last introducer is inserted will be measured using an MRI-compatible pulse oximeter.
|
After last introducer insertion, within 1 minute
|
Blood pressure after introducer sheath removal
Time Frame: After last introducer sheath removal, within 1 minute
|
Blood pressure (systolic/diastolic) after the last introducer sheath is removed will be measured using an MRI-compatible blood pressure cuff.
|
After last introducer sheath removal, within 1 minute
|
Pulse after introducer sheath removal
Time Frame: After last introducer sheath removal, within 1 minute
|
Heart rate after the last introducer sheath is removed will be measured using an MRI-compatible pulse oximeter.
|
After last introducer sheath removal, within 1 minute
|
Anxiety post-biopsy: State Anxiety Scale of the State-Trait Anxiety Inventory (STAI)
Time Frame: Post-biopsy, within 1 hour
|
The State Anxiety Scale of the State-Trait Anxiety Inventory (STAI) will assess the degree of anxiety post-biopsy.
Participants will rate each of the 20 items on a 5-point Likert scale, ranging from 1 (not at all) through 4 (very much).
Items will be summed, creating a total score (possible range: 20-80).
|
Post-biopsy, within 1 hour
|
Likelihood of cancer post-biopsy: Likelihood of cancer scale
Time Frame: Post-biopsy, within 1 hour
|
Likelihood of cancer will be assessed post-biopsy using a single-item scale.
Participants will be asked to indicate what they were told regarding the likelihood of cancer from the radiologist performing the biopsy on a scale from 0 (not applicable - they did not discuss this with me) to 5 (high likelihood of cancer).
|
Post-biopsy, within 1 hour
|
Distraction from pain during biopsy: Attention to pain scale
Time Frame: Post-biopsy, within 1 hour
|
Using a 2-item self-report measure, participants will rate 1) the amount of attention they paid to the pain during biopsy and 2) the extent to which they were able to distract themselves from the pain during biopsy on an 11-point scale, ranging from 0 (not at all) to 10 (very much).
An ''attention to pain" score (range -10 to +10) will be calculated by subtracting the ability to distract from pain from the amount of attention to pain.
The higher the score, the more attention paid to pain.
|
Post-biopsy, within 1 hour
|
Distraction from pain during biopsy: Time spent thinking about pain scale
Time Frame: Post-biopsy, within 1 hour
|
Participants will also be asked to rate how much time they spent thinking about pain during the biopsy procedure on an 11-point scale, ranging from 0 (none of the time) to 10 (all of the time).
|
Post-biopsy, within 1 hour
|
Relaxation during biopsy: Relaxation numerical rating scale (NRS)
Time Frame: Post-biopsy, within 1 hour
|
Participants will be asked to indicate how relaxed they were during the biopsy procedure on a scale, ranging from 0 (not relaxed) to 10 (extremely relaxed).
|
Post-biopsy, within 1 hour
|
Relaxation during biopsy: Tension Subscale of the Profile of Mood State Short-Form
Time Frame: Post-biopsy, within 1 hour
|
Participants will also be provided with a list of six adjectives (i.e., tense, on-edge, uneasy, restless, nervous, and anxious) from the Tension Subscale of the Profile of Mood State Short-Form and be asked to rate each of the adjectives on a 5-point Likert scale, ranging from 0 (not at all) to 4 (extremely).
|
Post-biopsy, within 1 hour
|
Pain coping strategies post-biopsy: Coping Strategies Questionnaire (CSQ)
Time Frame: Post-biopsy, within 1 hour
|
To assess the use of pain coping strategies during the biopsy procedure, participants will complete the 14-item Coping Strategies Questionnaire (CSQ).
Participants will rate how frequently they used seven pain coping strategies (two items per scale) during the procedure on a scale ranging from 0 (not at all) to 6 (a lot).
Items will be averaged, giving a total score on each scale ranging from 0 to 6 with higher scores indicating greater use of pain coping strategies.
|
Post-biopsy, within 1 hour
|
Self-efficacy for pain and anxiety during biopsy: Self-efficacy for pain and anxiety scale
Time Frame: Post-biopsy, within 1 hour
|
To assess self-efficacy for managing pain and anxiety during the biopsy procedure, participants will complete a 4-item scale.
Items will be rated on a 10-point scale from 0 (not certain) to 10 (very certain).
Items will be averaged to create a composite score, ranging from 0 to 10 with higher scores indicating greater self-efficacy.
|
Post-biopsy, within 1 hour
|
Anxiety 24 hours post-biopsy: State Anxiety Scale of the State-Trait Anxiety Inventory (STAI)
Time Frame: 24 hours post-biopsy
|
The State Anxiety Scale of the State-Trait Anxiety Inventory (STAI) will assess the degree of anxiety 24 hours post-biopsy.
Participants will rate each of the 20 items on a 5-point Likert scale, ranging from 1 (not at all) through 4 (very much).
Items will be summed, creating a total score (possible range: 20-80).
|
24 hours post-biopsy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Rebecca Shelby, Ph.D., Duke Psychiatry and Behavioral Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 16, 2018
Primary Completion (ACTUAL)
June 20, 2019
Study Completion (ACTUAL)
June 20, 2019
Study Registration Dates
First Submitted
February 26, 2019
First Submitted That Met QC Criteria
March 14, 2019
First Posted (ACTUAL)
March 15, 2019
Study Record Updates
Last Update Posted (ACTUAL)
September 25, 2020
Last Update Submitted That Met QC Criteria
September 23, 2020
Last Verified
November 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00100029
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
Clinical Trials on Controlled Breathing Intervention
-
Khon Kaen UniversityThai health promotion foundation.Terminated
-
Uppsala UniversityThe Swedish Research Council; Örebro County CouncilCompleted
-
Chinese University of Hong KongCompleted
-
Centre Hospitalier Universitaire de NīmesCompletedCollapsibility of the Inferior Vena CavaFrance
-
Royal Marsden NHS Foundation TrustCompleted
-
Manchester Metropolitan UniversityNot yet recruitingPulmonary Disease, Chronic ObstructiveChina
-
University of DelawareCompleted
-
National Institute of Diabetes and Digestive and...Completed
-
St. Vincent's Medical CenterInflammation Research Foundation, Marblehead, MA.; NeuroScience, Inc., Osceola...CompletedSleep DeprivationUnited States